Breast Cancer News
Top Stories
Rare Breast Cancer Could Be Deadly
POSTED: June 30, 2009Dear Dr. Gott: A friend of mine was recently diagnosed with inflammatory breast cancer. I have done some initial research online, and www.mayoclinic.com describes it as a "rare but aggressive type of breast cancer that develops rapidly." They also point out that the typical signs of breast cancer -- a lump or suspicious area -- are often absen...
Genomic Health Reports Favorable Commentary On Value Of Multigene Assays From The St. Gallen Expert Consensus Meeting On The Primary Treatment Of Early Breast Cancer
POSTED: June 26, 2009GENEVA, and REDWOOD CITY, California -- Genomic Health, Inc. today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer recommended for the first time that validated multigene assays, such as Oncotype DX(R), should be considered as an adjunct to standard measures in helping determine chemothera...
New Breast Cancer Study Findings Reported From Mayo Clinic
POSTED: June 26, 2009According to recent research published in the Menopause - the Journal of the North American Menopause Society, "Various nonestrogenic therapies have been found to be effective in mitigating hot flashes, but it has been unclear whether the efficacy varies by whether women have had breast cancer and/or were taking tarnoxifen. This Study used data from May...
Provectus Pharmaceuticals To Offer Compassionate Use Of PV-10 For Non-Visceral Indications In Cancer Patients
POSTED: June 23, 2009KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients. Initially, the compassionate ...
Many Breast Cancer Patients Take High Doses Of Antioxidants Despite Possible Consequences
POSTED: June 21, 2009A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown. Published in the July 15, 2009 issue of CANCER, a journal of the American Cancer Society, the study indicates that additional research should be undertaken to determine the effects of ...
UNC Study Identifies Genetic Cause Of Most Common Form Of Breast Cancer
POSTED: June 21, 2009Cancer is a disease of runaway cell proliferation. Normally, a variety of genes coordinate to keep cell growth under control and on track. If a gene goes awry at any step in the cell cycle, another can compensate to keep cancer from developing. Now researchers at the University of North Carolina at Chapel Hill School of Medicine and UNC Lineberger Co...
Phase II Trials Investigating Oral PARP Inhibitor, Olaparib, In BRCA-Deficient Advanced Breast And Ovarian Cancer
POSTED: June 21, 2009"These encouraging data demonstrate the potential for olaparib to make a significant impact on the outcomes of patients with BRCA-deficient breast and ovarian cancer. AstraZeneca is fully evaluating the development of this drug in these diseases, and is exploring its potential in other populations of patients with cancers associated with defective DNA r...
VBI Researchers Develop New Method For Breast Cancer Biomarker Discovery
POSTED: June 21, 2009Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated...
Women Underrepresented In Most Cancer Research
POSTED: June 21, 2009Women continue to be under-enrolled in cancer clinical trials, according to a new review, published in the July 15, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest that greater efforts are needed to ensure that oncologists know the true effects of treatments and medical procedures in female patie...
Galapagos Initiates Clinical Studies With GLPG0187, A Candidate Drug For Bone Metastasis
POSTED: June 16, 2009MECHELEN, BELGIUM -- Galapagos NV announced that today it has initiated Phase I clinical development of its integrin receptor antagonist (IRA), GLPG0187. This is the second small molecule therapeutic from Galapagos' internal drug discovery program to enter the clinic in 2009. Candidate drug GLPG0187 could offer a promising new therapeutic approa...
